Sponsors also need to carefully consider the resourcing requirements for preclinical testing, which include ensuring appropriate access to the most relevant databases, clinical samples, and preclinical models (cell lines and animal models). During clinical development, sponsors can account for the pharmacodynamic (PD)/pharmacokinetic (PK)…[Leer más]

2mg/kg/day [1.72-9.57]; r= -0.59; P< .001) and at end-stage heart failure (median 4.7mg/kg/day [2.02-7.28]; r= -0.62; P= .005). No significant hazard ratios were found for duration of hospitalization nor survival time for any of the electrolyte concentrations.

The observed association between serum chloride concentrations and diureti…[Leer más]

From the results obtained, it is evident that the biosurfactant could act as a potential antibiofilm agent against drug resistant C. albicans strains.SARS-CoV-2 Mpro, also known as the main protease or 3C-like protease, is a key enzyme involved in the replication process of the virus that is causing the COVID-19 pandemic. It is also the most…[Leer más]